Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir vs Valganciclovir for CMV in HSCT Recipients (AURORA)
NCT02927067Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of maribavir in cytomegalovirus infection (CMV) (2 arms), sponsored by Takeda. Primary endpoint: Confirmed Clearance of Plasma CMV DNA at Week 8. Started Apr 2017; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02927067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927067.